These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2609 related articles for article (PubMed ID: 25203083)

  • 1. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
    Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
    JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
    Fortin PM; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
    Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
    Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Doree C; Abboud MR
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012389. PubMed ID: 28500860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Wang WC
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD003146. PubMed ID: 28094851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Estcourt LJ; Kohli R; Hopewell S; Trivella M; Wang WC
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003146. PubMed ID: 32716555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
    Rankine-Mullings AE; Nevitt SJ
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD002202. PubMed ID: 36047926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
    Nevitt SJ; Jones AP; Howard J
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Sickle Cell Disease: Recommendations from the 2014 Expert Panel Report.
    Yawn BP; John-Sowah J
    Am Fam Physician; 2015 Dec; 92(12):1069-76. PubMed ID: 26760593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
    Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
    Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Wang WC; Dwan K
    Cochrane Database Syst Rev; 2013 Nov; (11):CD003146. PubMed ID: 24226646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
    Kang HA; Barner JC
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448
    [No Abstract]   [Full Text] [Related]  

  • 14. Big strokes in small persons.
    Adams RJ
    Arch Neurol; 2007 Nov; 64(11):1567-74. PubMed ID: 17998439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.
    Kassim AA; DeBaun MR
    Expert Opin Pharmacother; 2014 Feb; 15(3):325-36. PubMed ID: 24392871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: The last 40 years.
    Chaturvedi S; DeBaun MR
    Am J Hematol; 2016 Jan; 91(1):5-14. PubMed ID: 26547630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019.
    Tang AY; Zhou M; Maillis AN; Lai KW; Lane PA; Snyder AB
    Pediatr Blood Cancer; 2023 Mar; 70(3):e30152. PubMed ID: 36579749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
    Blinder MA; Vekeman F; Sasane M; Trahey A; Paley C; Duh MS
    Pediatr Blood Cancer; 2013 May; 60(5):828-35. PubMed ID: 23335275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evidence-based approach to the treatment of adults with sickle cell disease.
    Lottenberg R; Hassell KL
    Hematology Am Soc Hematol Educ Program; 2005; ():58-65. PubMed ID: 16304360
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 131.